What is the revenue and EPS growth rate for Ginkgo Bioworks year over year?

What is Ginkgo Bioworks's gross profit margin?

What is Ginkgo Bioworks's latest dividend and current dividend yield?

What guidance did Ginkgo Bioworks's management provide for the next earnings period?

What does Ginkgo Bioworks do and what are its main business segments?

What were the key takeaways from Ginkgo Bioworks's earnings call?

Did Ginkgo Bioworks beat or miss consensus estimates last quarter?

What were the key takeaways from Ginkgo Bioworks’s earnings call?

- **AI Lab Automation**: Ginkgo's RAC system enables AI models to control lab experiments via standardized robotics.
- **Government Growth**: 20%+ revenue from U.S. grants, $22M BARDA award for antibody manufacturing.
- **Cash Efficiency**: Q3 2025 cash burn $28M (-75% YoY), $462M cash with no debt.
- **Future Labs Partnership**: Collaborating with FutureHouse to develop AI scientists that design and execute experiments.

**【Management Opening Remarks】**
- CEO Jason Kelly highlighted three strategic objectives: delivering autonomous lab robotics, expanding the Boston RAC lab, and offering frontier AI-driven biotech services.
- CFO Steve Coen reported a strong cash position of $462M with no debt, down 75% YoY in cash burn due to restructuring.

**【CEO Strategic Vision】**
- **AI & Automation Integration**: Ginkgo's RAC (reconfigurable automation carts) enable AI models to control lab experiments via standardized, plug-and-play robotics.
- **Government & Pharma Expansion**: Won $22M BARDA contract for antibody manufacturing and partnered with Bayer for microbial fertilizers.
- **Future Labs Collaboration**: Partnered with FutureHouse to develop AI models that design and execute experiments using Ginkgo's automation.

**【CFO Financial Update】**
- **Revenue Decline**: Cell Engineering revenue $29M (-61% YoY), Biosecurity $9M (19% margin).
- **Cost Efficiency**: G&A expenses down 47%, R&D down 8%, net loss $56M (-140% YoY).
- **Cash Management**: Q3 2025 cash burn $28M vs. $114M prior year, driven by program rationalization.

**【Q&A Highlights】**
- **Government Exposure**: 20%+ revenue from U.S. grants, unaffected by shutdown.
- **RAC Rollout**: Target 100+ RACs in Boston lab by end-2026, demoing protein expression protocols.
- **2030 Vision**: 80% tools (robotics, AI) vs. 20% services; biosecurity could grow if CDC adopts monitoring tech.
- **Google Reset**: Reduced cloud commitment by $100M, extended term to 6 years to align with slower bio-AI adoption.

Ginkgo Bioworks Holdings, Inc.(DNA)-20251107-2025 Q3 Earnings call transcript

Cell Engineering

Biosecurity

DNA

DNA fundamentals

You can ask Aime